<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Mol Pharm</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Molecular pharmaceutics</journal-title></journal-title-group><issn pub-type="ppub">1543-8384</issn><issn pub-type="epub">1543-8392</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10228092</article-id><article-id pub-id-type="pmcid-ver">PMC10228092.1</article-id><article-id pub-id-type="pmcaid">10228092</article-id><article-id pub-id-type="pmcaiid">10228092</article-id><article-id pub-id-type="manuscript-id">NIHMS1891174</article-id><article-id pub-id-type="pmid">36279508</article-id><article-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c00490</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1891174</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1891174</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development of an In Vitro System To Emulate an In Vivo Subcutaneous Environment: Small Molecule Drug Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0218-6382</contrib-id><name name-style="western"><surname>Lou</surname><given-names initials="H">Hao</given-names></name><aff id="A1">Department of Pharmaceutical Chemistry and Biopharmaceutical Innovation and Optimization Center, University of Kansas, Lawrence, Kansas 66047, United States</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0824-6577</contrib-id><name name-style="western"><surname>Hageman</surname><given-names initials="MJ">Michael J.</given-names></name><aff id="A2">Department of Pharmaceutical Chemistry and Biopharmaceutical Innovation and Optimization Center, University of Kansas, Lawrence, Kansas 66047, United States</aff></contrib></contrib-group><author-notes><corresp id="CR1"><bold>Corresponding Authors</bold><email>lou0@ku.edu</email>, <email>mhageman@ku.edu</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P36">The authors declare no competing financial interest.</p></fn></author-notes><pub-date pub-type="ppub"><day>07</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>24</day><month>10</month><year>2022</year></pub-date><volume>19</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">436880</issue-id><fpage>4017</fpage><lpage>4025</lpage><pub-history><event event-type="nihms-submitted"><date><day>06</day><month>05</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>30</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>30</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 12:25:14.010"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1891174.pdf"/><abstract id="ABS1"><p id="P1">A reliable in vitro system can support and guide the development of subcutaneous (SC) drug products. Although several in vitro systems have been developed, they have some limitations, which may hinder them from getting more engaged in SC drug product development. This study sought to develop a novel in vitro system, namely, <underline>E</underline>mulator of <underline>S</underline>ub<underline>C</underline>utaneous <underline>A</underline>bsorption and <underline>R</underline>elease (ESCAR), to better emulate the in vivo SC environment and predict the fate of drugs in SC delivery. ESCAR was designed using computer-aided design (CAD) software and fabricated using the three-dimensional (3D) printing technique. ESCAR has a design of two acceptor chambers representing the blood uptake pathway and the lymphatic uptake pathway, respectively, although only the blood uptake pathway was investigated for small molecules in this study. Via conducting a DoE factor screening study using acetaminophen solution, the relationship of the output (drug release from the &#8220;SC&#8221; chamber to the &#8220;blood circulation&#8221; chamber) and the input parameters could be modeled using a variety of methods, including polynomial equations, machine learning methods, and Monte Carlo simulation-based methods. The results suggested that the hyaluronic acid (HA) concentration was a critical parameter, whereas the influence of the injection volume and injection position was not substantial. An in vitro&#8211;in vivo correlation (IVIVC) study was developed using griseofulvin suspension to explore the feasibility of applying ESCAR in formulation development and bioequivalence studies. The developed LEVEL A IVIVC model demonstrated that the in vivo PK profile could be correlated with the in vitro release profile. Therefore, using this model, for new formulations, only in vitro studies need to be conducted in ESCAR, and in vivo studies might be waived. In conclusion, ESCAR had important implications for research and development and quality control of SC drug products. Future work would be focused on further optimizing ESCAR and expanding its applications via assessing more types of molecules and formulations.</p></abstract><abstract id="ABS2" abstract-type="graphical"><title>Graphical Abstract</title><p id="P2">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="nihms-1891174-f0004.jpg"/>
</p></abstract><kwd-group><kwd>subcutaneous route of administration</kwd><kwd>in vitro system</kwd><kwd>3D printing</kwd><kwd>in vitro&#8211;in vivo correlation (IVIVC)</kwd><kwd>machine learning</kwd><kwd>Monte Carlo simulation</kwd><kwd>Design of Experiment (DoE)</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>